2 news items
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BPTH
18 Apr 24
Investigator for the Phase 1/1b trial. Dr. Roboz is a professor of medicine and director of the Clinical and Translational Leukemia Program
Bio-Path Holdings Provides 2024 Clinical and Operational Update
BPTH
2 Apr 24
Administration (FDA) later in the year in an Investigational New Drug (IND) application. Development of Molecular
- Prev
- 1
- Next